SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Clinical trials for SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA trials appear
Sign up with your email to follow new studies for SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for tough brain cancers: testing a Two-Pronged attack
Disease control Recruiting nowThis study is testing whether a combination of two drugs, zanubrutinib and pemetrexed, can help control brain lymphomas that have returned or stopped responding to other treatments. The goal is to see if this approach is safe and can shrink tumors and help people live longer. The…
Matched conditions: SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE2 • Sponsor: Baptist Health South Florida • Aim: Disease control
Last updated Apr 02, 2026 14:58 UTC
-
New strategy aims to stop aggressive lymphoma from coming back
Disease control Recruiting nowThis study is testing whether adding a maintenance drug called acalabrutinib after cellular therapies (like stem cell transplants or CAR-T cell therapy) can help prevent aggressive lymphoma from returning in patients at very high risk of relapse. Researchers want to see if this e…
Matched conditions: SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
Early trial tests new hope for Tough-to-Treat brain cancers
Disease control Recruiting nowThis early-stage study is testing whether combining two drugs, epcoritamab and ibrutinib, is safe for people with lymphoma that has returned in or spread to the brain after prior treatment. The main goal is to find a dose that causes few or manageable side effects. It will includ…
Matched conditions: SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New immune therapy targets brain cancer in early trial
Disease control Recruiting nowThis early-stage study is testing the safety and side effects of a new two-part drug treatment for lymphoma that has spread to the brain or spinal cord. The treatment involves an antibody called glofitamab, which is designed to help the body's own immune cells find and attack the…
Matched conditions: SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
Tracking the Mind's journey: can brain radiation for cancer affect memory?
Knowledge-focused Recruiting nowThis study aims to understand how whole brain radiation therapy affects memory, thinking, and quality of life in patients with blood cancers like lymphoma and leukemia. Researchers will follow 100 adult patients for up to 5 years, using standard memory tests, questionnaires, and …
Matched conditions: SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:35 UTC